Effects of Forgiveness-Based Group Psychoeducation Applied to Cancer Survivors
Launched by HILAL MERVE BELEN · Mar 4, 2025
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study was designed as a randomized controlled experimental study with a pre-test-post-test and follow-up design to examine the effects of forgiveness-based group psychoeducation on fear of cancer recurrence, forgiveness and psychiatric symptoms of cancer survivors.
The aim is to evaluate the effects of a forgiveness-based psychoeducation program on cancer survivors. After the "Informed Voluntary Consent Form" is obtained from individuals who agree to participate in the study, the Introductory Information Form, Heartland Forgiveness Scale, Fear of Relapse Inventory and Brief Symptom In...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written and verbal consent to participate in the study
- • Understanding and speaking Turkish
- • Being over 18 years old
- • Not having any visual, hearing or mental disabilities
- • Having been diagnosed with cancer, treated with curative intent and having completed major treatments (surgery, radiotherapy, chemotherapy) within the last 5 years
- Exclusion Criteria:
- • Not volunteering to participate in research
- • Having a visual, hearing or mental disability
- • Agreeing to participate in another psychoeducational program conducted simultaneously with the research
- • Inability to communicate in Turkish
- • Having previously received training in forgiveness and/or coping with fear of relapse
About Hilal Merve Belen
Hilal Merve Belen is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on fostering collaboration between researchers, healthcare professionals, and regulatory bodies, the organization aims to streamline the clinical trial process while adhering to the highest ethical standards and regulatory compliance. By leveraging cutting-edge methodologies and a patient-centric approach, Hilal Merve Belen strives to accelerate the development of safe and effective treatments across various therapeutic areas, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Keçiören, Turkey
Ankara, , Turkey
Patients applied
Trial Officials
Gamze Sarıkoç, Associate Professor
Study Director
Saglik Bilimleri Universitesi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported